Ocugen reports positive 12-Month phase 2 ArMaDa results for geographic atrophy
Share
Ocugen (NASDAQ:OCGN) today announced positive 12-month results from its Phase 2 ArMaDa clinical trial evaluating OCU410 (AAV-hRORA), a modifier gene therapy for the treatment of Geographic Atrophy (GA) secondary to dry Age-Related Macular Degeneration (dAMD).
